uk 68798 has been researched along with mexiletine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Raberger, G; Schütz, W; Todt, H; Zojer, N | 1 |
| Brown, AM; Cantù, F; Napolitano, C; Priori, SG; Schwartz, PJ | 1 |
| Cantù, F; Priori, SG; Schwartz, PJ | 1 |
| Cantù, F; Napolitano, C; Paganini, V; Priori, SG; Schwartz, PJ | 1 |
| Blinova, K; Chan, D; Crumb, WJ; Erato, C; Florian, J; Guo, P; Hong, M; Johannesen, L; Lin, J; Mason, JW; Mutlib, A; Sanabria, C; Stockbridge, N; Stohlman, J; Strauss, DG; Ugander, M; Vicente, J; Waite-Labott, K; Wang, J | 1 |
| Hosseini, M; Johannesen, L; Mason, JW; Pueyo, E; Sager, PT; Strauss, DG; Vicente, J | 1 |
| Bergau, D; Bystricky, W; Carter, D; Gintant, G; Kamradt, K; Maier, C; Welsh, P | 1 |
| Ackerman, MJ; Das, S; Hamrick, SK; Kim, M; Pradhananga, S; Sager, PT; Srinivasan, D; Tester, DJ | 1 |
2 review(s) available for uk 68798 and mexiletine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Molecular biology of the long QT syndrome: impact on management.
Topics: Action Potentials; Adrenergic Antagonists; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Cardiotonic Agents; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 7; Disease Models, Animal; Electrocardiography; Genetic Therapy; Guinea Pigs; Heart Rate; Humans; Intercellular Signaling Peptides and Proteins; Long QT Syndrome; Mexiletine; Molecular Biology; Myocardium; Peptides; Phenethylamines; Potassium; Potassium Channel Blockers; Potassium Channels; Receptors, Adrenergic; Risk Factors; Sodium Channel Blockers; Sodium Channels; Sulfonamides; Syncope; Tachycardia, Ventricular | 1997 |
3 trial(s) available for uk 68798 and mexiletine
| Article | Year |
|---|---|
Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
Topics: Adult; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cross-Over Studies; Diltiazem; Drug Therapy, Combination; Electrocardiography; Ether-A-Go-Go Potassium Channels; Female; Fluoroquinolones; Heart Rate; Humans; Lidocaine; Long QT Syndrome; Male; Mexiletine; Moxifloxacin; Phenethylamines; Prospective Studies; Sodium Channel Blockers; Sulfonamides; Young Adult | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go Potassium Channels; Female; Heart; Heart Rate; Humans; Lidocaine; Long QT Syndrome; Male; Mexiletine; Phenethylamines; Potassium Channel Blockers; Sodium; Sodium Channel Blockers; Sulfonamides; Torsades de Pointes; Verapamil | 2016 |
T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization.
Topics: Action Potentials; Adult; Databases, Factual; Double-Blind Method; Electrocardiography; Female; Heart; Humans; Lidocaine; Male; Mexiletine; Phenethylamines; Potassium Channel Blockers; Ranolazine; Sodium Channel Blockers; Sulfonamides; Verapamil; Young Adult | 2019 |
9 other study(ies) available for uk 68798 and mexiletine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Prolongation of the QT interval by dofetilide modulates rate-dependent effects of mexiletine on intraventricular conduction.
Topics: Action Potentials; Animal Welfare; Animals; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Drug Synergism; Female; Guinea Pigs; Heart Conduction System; Injections, Intravenous; Male; Mathematics; Mexiletine; Phenethylamines; Sodium Channel Blockers; Sulfonamides | 1994 |
Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome.
Topics: Action Potentials; Animals; Cardiac Pacing, Artificial; Cation Transport Proteins; Ether-A-Go-Go Potassium Channels; Guinea Pigs; Intercellular Signaling Peptides and Proteins; Isoproterenol; Long QT Syndrome; Mexiletine; Mutation; Peptides; Phenethylamines; Potassium Channels; Potassium Channels, Voltage-Gated; Receptors, Adrenergic, beta; Sodium Channel Blockers; Sodium Channels; Sulfonamides | 1996 |
The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology.
Topics: Animals; Anti-Arrhythmia Agents; Cardiotonic Agents; Cation Transport Proteins; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; Heart Ventricles; Humans; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Long QT Syndrome; Mexiletine; Peptides; Phenethylamines; Point Mutation; Potassium Channels; Potassium Channels, Voltage-Gated; Sea Anemones; Sodium Channels; Sulfonamides; Trans-Activators; Transcriptional Regulator ERG | 1996 |
SGK1 inhibition attenuates the action potential duration in reengineered heart cell models of drug-induced QT prolongation.
Topics: Action Potentials; Humans; Long QT Syndrome; Mexiletine; Myocytes, Cardiac; Sulfonamides | 2023 |